Trial · NCT06434467
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
NCT06434467, Phase 3, Unknown, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma. Trials, record NCT06434467. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06434467
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
- NCT number
- NCT06434467
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 83 participants, estimated
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions
- T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma
- Interventions
- Nelarabine injection
- First posted
- 2024-05-30
- Last updated
- 2024-05-30
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite complete response rate (CCR) assessed by the Independent Review Committee (IRC) | During the study period (Baseline up to two months) | Proportion of complete responses (CCR) after 2 cycles of antineoplastic therapy as determined by independent review committee (IRC) assessment |
| Secondary | Composite complete response rate (CCR) assessed by the investigator | During the study period (Baseline up to two months) | Proportion of complete responses (CCR) after 2 cycles of antineoplastic therapy as determined by the investigator. |
| Secondary | Objective Remission Rate (ORR) | During the study period (Baseline up to two months) | The best Objective Remission Rate (ORR) for both complete response (CR) and partial response (PR) cases within 2 cycles. |
| Secondary | Duration of complete remission (DOCR) | During the study period (Baseline up to two years) | Proportion of patients whose tumor shrinks or stabilizes for some time, including cases of complete response (CR), partial response (PR), and stable disease (SD). |
| Secondary | Disease-free survival (DFS) | During the study period (Baseline up to two years) | It refers to the time from the first day of absence of disease to the recurrence of disease. |
| Secondary | Overall survival (OS) | During the study period (Baseline up to two years) | It indicates the time interval from randomization to death from any cause. |
| Secondary | Incidence of adverse events (AEs) | During the study period (Baseline up to two years) | Adverse events refer to all adverse medical events that occur after a patient or clinical trial subject receives an experimental drug, which can be expressed as symptoms, signs, diseases, or abnormalities in laboratory tests, but are not necessarily related to the treatment of the experimental drug. |
| Secondary | Incidence of serious adverse events (SAEs) | During the study period (Baseline up to two years) | Serious adverse events include death, life-threatening, permanent or serious disability or loss of function, hospitalization or prolonged hospitalization, and adverse medical conditions such as congenital abnormalities or birth defects. |
| Secondary | Peak time (Tmax) | During the study period (Baseline up to two years) | Time to maximum plasma concentration. |
| Secondary | Peak concentration(Cmax) | During the study period (Baseline up to two years) | Pharmacokinetic parameters, including but not limited to: Peak concentration(Cmax) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06434467
GET https://conductscience.org/api/trials/v1/NCT06434467/registered